YKL-5-124

Overview

YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC 50 s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH , respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2 , and inactive against CDK12 and CDK13 . YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status.

Application

Products | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-101257
• CAS No.: 1957203-01-8
• Molecular Formula: C28H33N7O3
• Molecular Weight: 515.61
• Purity: 99.53%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (4.03 mM); Clear solution
• Availability: In-stock

Source

Original product source